Literature DB >> 21063829

[Vaccinations in rheumatology].

M Feuchtenberger1, R E Voll, C Kneitz.   

Abstract

Patients with autoimmune or rheumatic diseases are at increased risk for infectious complications due to immunosuppressive therapy and/or the underlying immunological disease itself. To date, the consistent use of vaccinations in this patient group has been limited due to concerns about flair-ups or lack of efficacy. In prospective studies neither an increased risk of disease flair-ups nor of initiation of autoimmune disorders was found as yet; however, the data is still considered insufficient (small studies including only patients in remission). Vaccination with non-live vaccines can generally be regarded as safe and relatively effective, even in patients on immunosuppressive therapy. Since the immune response to vaccination may be markedly impaired depending on the medication used and the underlying autoimmune disease, monitoring of both serum titers and of patients' vaccination schedules should form an integral part of rheumatological care.

Entities:  

Mesh:

Year:  2010        PMID: 21063829     DOI: 10.1007/s00393-010-0707-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  33 in total

1.  Specific antibody response after influenza immunization in systemic lupus erythematosus.

Authors:  Mahmoud Abu-Shakra; Joseph Press; Noemi Varsano; Virginia Levy; Ella Mendelson; Shaul Sukenik; Dan Buskila
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.

Authors:  M C Kapetanovic; T Saxne; J-A Nilsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2006-11-18       Impact factor: 7.580

3.  Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine.

Authors:  A I Sanchez-Fructuoso; D Prats; P Naranjo; C Fernández-Pérez; M J González; A Mariano; J González; M A Figueredo; J M Martin; V Paniagua; J Fereres; E Gómez de la Concha; A Barrientos
Journal:  Transplantation       Date:  2000-02-15       Impact factor: 4.939

4.  Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.

Authors:  L B S Gelinck; Y K O Teng; G F Rimmelzwaan; B J F van den Bemt; F P Kroon; J M van Laar
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

Review 5.  Rituximab-associated infections.

Authors:  Juan C Gea-Banacloche
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

6.  A case-control study of serious autoimmune adverse events following hepatitis B immunization.

Authors:  David A Geier; Mark R Geier
Journal:  Autoimmunity       Date:  2005-06       Impact factor: 2.815

7.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors:  Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal:  Arthritis Rheum       Date:  2006-05

8.  Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  Ori Elkayam; Daphna Paran; Dan Caspi; Irena Litinsky; Michael Yaron; Darlene Charboneau; Jeffrey B Rubins
Journal:  Clin Infect Dis       Date:  2001-12-04       Impact factor: 9.079

9.  Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation.

Authors:  Roland Meisel; Lisa Kuypers; Uta Dirksen; Ralf Schubert; Bernd Gruhn; Gabriele Strauss; Karin Beutel; Andreas H Groll; Ulrich Duffner; Renate Blütters-Sawatzki; Wolfgang Holter; Tobias Feuchtinger; Hans-Peter Grüttner; Horst Schroten; Stefan Zielen; Christian Ohmann; Hans-Jürgen Laws; Dagmar Dilloo
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

10.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01
View more
  4 in total

1.  [Biologicals 2012].

Authors:  M Gaubitz
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

Review 2.  [Vaccination prior to travelling for patients with rheumatic diseases].

Authors:  B Ehrenstein
Journal:  Z Rheumatol       Date:  2011-06       Impact factor: 1.372

3.  [Role of orthopedic rheumatologist in the therapy of rheumatic diseases with biologics].

Authors:  S Rehart; M Henniger
Journal:  Orthopade       Date:  2014-06       Impact factor: 1.087

4.  [How well are patients with inflammatory rheumatic diseases protected against measles?]

Authors:  U Kiltz; A Celik; S Tsiami; X Baraliakos; I Andreica; D Kiefer; B Bühring; J Braun
Journal:  Z Rheumatol       Date:  2020-09-15       Impact factor: 1.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.